Daratumumab Plus Bortezomib, Melphalan, and Prednisone Versus Standard of Care in Latin America for Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Propensity Score Matching Analysis

INTRODUCTION: The phase 3 ALCYONE study demonstrated significantly longer progression-free and overall survival (PFS/OS) and higher overall response rates (ORR) with daratumumab plus bortezomib, melphalan, and prednisone (D-VMP) versus VMP alone in transplant-ineligible patients with newly diagnosed...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Adv Ther
Auteurs principaux: Hungria, Vania, Martínez-Baños, Deborah M., Mateos, María-Victoria, Dimopoulos, Meletios A., Cavo, Michele, Heeg, Bart, Garcia, Andrea, Lam, Annette, Machnicki, Gerardo, He, Jianming, Fernandez, Mariana
Format: Artigo
Langue:Inglês
Publié: Springer Healthcare 2020
Sujets:
Original Research
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC7595972/
https://ncbi.nlm.nih.gov/pubmed/33067698
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s12325-020-01521-9
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires